BIOPHARMA
By
Is AI-Engineered HMBD-002 the Next Big Immunotherapy? Hummingbird Bioscience Signs $290M Global Licensing Deal with Percheron Therapeutics
Key Highlights Strategic Global Licensing Deal Hummingbird Bioscience has signed a worldwide licensing agreement with Percheron Therapeutics for…
Can ProFound Therapeutics and Novartis’ $750M AI-Driven Cardiovascular Pact Redefine Drug Discovery from the Human Proteome?
Key Highlights AI Meets Proteomics: A New Paradigm in Cardiovascular DiscoveryIn a bold step toward AI-enabled medicine, ProFound…
Is Insilico’s AI-Driven UAE University Alliance the Catalyst for a New Generation of Biotech Talent?
Key Highlights Academic Meets AI Innovation in UAEInsilico Medicine, a leader in generative AI for drug discovery, has…
Is Sanofi’s $632M AI Bet on Formation Bio the Next Big Immunology Breakthrough?
French pharma giant doubles down on AI-native R&D with gusacitinib licensing deal targeting new inflammatory indication Key Takeaways…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize Surgery, Drug Discovery, and Global Patient Care?
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI use cases, Johnson…
